HXBM (Helix Biomedix) Cyclically Adjusted PS Ratio: (As of Aug. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Helix Biomedix Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Helix Biomedix  (OTCPK:HXBM) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Helix Biomedix Cyclically Adjusted PS Ratio Related Terms


Helix Biomedix Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Helix Biomedix's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix Biomedix Cyclically Adjusted PS Ratio Chart

Helix Biomedix Annual Data
Trend Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Helix Biomedix Quarterly Data
Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HXBM vs XBIO, CBLI, ADYX: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Helix Biomedix's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Helix Biomedix Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix Biomedix's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Helix Biomedix's Cyclically Adjusted PS Ratio falls into.



Helix Biomedix Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Helix Biomedix's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2012 is calculated as:

For example, Helix Biomedix's adjusted Revenue per Share data for the three months ended in Sep. 2012 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2012 (Change)*Current CPI (Sep. 2012)
=2.825/231.4070*231.4070
=2.825

Current CPI (Sep. 2012) = 231.4070.

Helix Biomedix Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200212 0.000 180.900 0.000
200303 0.057 184.200 0.072
200306 1.114 183.700 1.403
200309 0.683 185.200 0.853
200312 0.594 184.300 0.746
200403 0.512 187.400 0.632
200406 1.000 189.700 1.220
200409 0.578 189.900 0.704
200412 0.043 190.300 0.052
200503 0.000 193.300 0.000
200506 0.982 194.500 1.168
200509 0.597 198.800 0.695
200512 0.194 196.800 0.228
200603 0.257 199.800 0.298
200606 0.395 202.900 0.450
200609 0.250 202.900 0.285
200612 0.053 201.800 0.061
200703 0.734 205.352 0.827
200706 1.640 208.352 1.821
200709 1.849 208.490 2.052
200712 1.221 210.036 1.345
200803 2.791 213.528 3.025
200806 1.012 218.815 1.070
200809 1.826 218.783 1.931
200812 0.919 210.228 1.012
200903 1.012 212.709 1.101
200906 1.605 215.693 1.722
200909 1.140 215.969 1.221
200912 0.791 215.949 0.848
201003 0.814 217.631 0.866
201006 3.837 217.965 4.074
201009 1.093 218.439 1.158
201012 3.410 219.179 3.600
201103 2.157 223.467 2.234
201106 4.175 225.722 4.280
201109 2.380 226.889 2.427
201112 2.687 225.672 2.755
201203 4.096 229.392 4.132
201206 2.837 229.478 2.861
201209 2.825 231.407 2.825

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Helix Biomedix Business Description

Address 19125 North Creek Parkway, Suite 120, Bothell, WA, USA, 98011
Helix Biomedix Inc is a Delaware-based biopharmaceutical company that focuses on the early-stage development of peptide-based therapeutics for dermatology and skin health. The Company is in the preclinical stage, advancing a rare disease drug program for xeroderma pigmentosum, and plans to seek orphan drug designation before entering clinical development. Leveraging its proprietary peptide technology, Helix BioMedix aims to address unmet needs in rare dermatological conditions and has a history of developing patented bioactive peptides for topical personal care use.